These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 28487127)
1. Design and synthesis of pyrazolo[3,4-d]pyrimidines: Nitric oxide releasing compounds targeting hepatocellular carcinoma. Elshaier YAMM; Shaaban MA; Abd El Hamid MK; Abdelrahman MH; Abou-Salim MA; Elgazwi SM; Halaweish F Bioorg Med Chem; 2017 Jun; 25(12):2956-2970. PubMed ID: 28487127 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives. Bakr RB; Mehany ABM; Abdellatif KRA Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular carcinoma. Abou-Salim MA; Shaaban MA; Abd El Hameid MK; Elshaier YAMM; Halaweish F Bioorg Chem; 2019 Apr; 85():515-533. PubMed ID: 30807895 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma. Harras MF; Sabour R Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429 [TBL] [Abstract][Full Text] [Related]
6. Some pyrazole and pyrazolo[3,4-d]pyrimidine derivatives: synthesis and anticancer evaluation. Shamroukh AH; Rashad AE; Abdel-Megeid RE; Ali HS; Ali MM Arch Pharm (Weinheim); 2014 Aug; 347(8):559-65. PubMed ID: 24801813 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
8. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis. Maher M; Kassab AE; Zaher AF; Mahmoud Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of pyrazolo[4,3-d]pyrimidine analogues. Yuan L; Song C; Li C; Li Y; Dong L; Yin S Eur J Med Chem; 2013 Sep; 67():152-7. PubMed ID: 23851116 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and anti-hepatocellular carcinoma activity of novel O Zou Y; Yan C; Liu JC; Huang ZJ; Xu JY; Zhou JP; Zhang HB; Zhang YH Chin J Nat Med; 2017 Dec; 15(12):928-937. PubMed ID: 29329650 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity. Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel hybrids targeting mTOR and HDACs for potential treatment of hepatocellular carcinoma. Zhai S; Zhang H; Chen R; Wu J; Ai D; Tao S; Cai Y; Zhang JQ; Wang L Eur J Med Chem; 2021 Dec; 225():113824. PubMed ID: 34509167 [TBL] [Abstract][Full Text] [Related]
13. Keshari AK; Singh AK; Raj V; Rai A; Trivedi P; Ghosh B; Kumar U; Rawat A; Kumar D; Saha S Drug Des Devel Ther; 2017; 11():1623-1642. PubMed ID: 28615927 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and in-vitro anti-proliferative evaluation of some pyrazolo[1,5-a]pyrimidines as novel larotrectinib analogs. Attia MH; Elrazaz EZ; El-Emam SZ; Taher AT; Abdel-Aziz HA; Abouzid KAM Bioorg Chem; 2020 Jan; 94():103458. PubMed ID: 31785854 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors. Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and in vitro antiproliferative activity of certain novel pyrazolo[3,4-b]pyridines with potential p38α MAPK-inhibitory activity. Farahat AA; Samir EM; Zaki MY; Serya RAT; Abdel-Aziz HA Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100302. PubMed ID: 34796536 [TBL] [Abstract][Full Text] [Related]
17. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma. Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, molecular modelling, and biological evaluation of novel substituted pyrimidine derivatives as potential anticancer agents for hepatocellular carcinoma. Ahmed NM; Youns M; Soltan MK; Said AM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1110-1120. PubMed ID: 31117890 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, anticancer assessment on human breast, liver and colon carcinoma cell lines and molecular modeling study using novel pyrazolo[4,3-c]pyridine derivatives. Metwally NH; Deeb EA Bioorg Chem; 2018 Apr; 77():203-214. PubMed ID: 29367077 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and anticancer evaluation of novel pyrazole, pyrazolo[3,4-d]pyrimidine and their glycoside derivatives. Nassar IF; El Farargy AF; Abdelrazek FM; Ismail NSM Nucleosides Nucleotides Nucleic Acids; 2017 Apr; 36(4):275-291. PubMed ID: 28323527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]